MedTrace Logo

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

NCT01016834 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2011-12-29

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.

Conditions

Interventions

DEVICE

Sumavel DosePro

Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration

DRUG

Sumatriptan

subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period

Sponsors & Collaborators

  • Synteract, Inc.

    collaborator INDUSTRY

  • Zogenix, Inc.

    lead INDUSTRY

Principal Investigators

  • Roger K Cady, MD · Clinvest

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01016834 on ClinicalTrials.gov